Theriva Biologics earnings release, August 11, 2026
Theriva™ Biologics Reports Second Quarter
2026 Operational Highlights and Financial Results – First patients dosed in the VIRAGE2 Phase
2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients – – Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1 2027 – Rockville, MD, August 11, 2026 (GLOBE NEWSWIRE) – Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.
“We have successfully converted last quarter’s regulatory achievements into clinical progress in the VCN-01 program,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics.
“Dosing of the first patients in the VIRAGE2 trial brings us closer to refining a VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 clinical trial in first-line metastatic PDAC patients when coadministered with chemotherapy. A repeated VCN-01 dosing regimen may also improve outcomes when combined with other cancer interventions, including immuno-oncology products, RAS inhibitors, and other emerging classes of cancer treatments. If more frequent repeated administration of VCN-01 is feasible and well-tolerated, use of this dosing regimen may further derisk future Phase 3 clinical trials.”
Recent Highlights and Anticipated Milestones
VCN-01
Metastatic PDAC:
Retinoblastoma:
Head & Neck Squamous Cell Carcinoma:
Second Quarter Ended June 30, 2026 Financial
Results
General and Administrative Expenses
General and administrative expenses decreased to $2.0 million for the three months ended June 30, 2026, from $11.2 million for the three months ended June 30, 2025. This decrease of 82% is primarily comprised of the prior year increase in fair value of the contingent consideration adjustment of $9.2 million due to the VIRAGE Phase 2b clinical trial of VCN-01 in PDAC achieving its primary survival and safety endpoints, offset set by current year increase in legal fees. The charge related to stock-based compensation expense was $110,000 for the three months ended June 30,
2026, compared to $97,000 for the three months ended June 30, 2025.
Research and Development Expenses
Research and development expenses decreased to
$1.3 million for the three months ended June 30, 2026, from $2.0 million for the three months ended June 30, 2025. This decrease of 35% is primarily the result of lower indirect cost related to compensation expense and lower direct clinical trial expenses related to the Company’s Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic HCT recipients and lower expenses related to SYN-020, offset by higher direct expenses related to VCN-01 manufacturing activities and expenses associated with the planning for the Phase 2a study in metastatic PDAC patients evaluating more frequent VCN-01 dosing for a longer period.
Other Income/Expense
Other income was $78,000 for the three months ended June 30, 2026, compared to other income of $74,000 for the three months ended June 30, 2025. Other income for the three months ended June 30, 2026 is comprised of interest income of $79,000 and an exchange loss of $1,000. Other income for the three months ended June 30, 2025 is comprised of interest income of $54,000 and an exchange gain of $20,000.
Cash and Cash Equivalents
Cash and cash equivalents totaled $11.3 million as of June 30, 2026, a decrease of $1.7 million from December 31, 2025. During the year ended December 31, 2025 and the quarter ended June 30, 2026, the primary use of cash was for working capital requirements and operating activities, which resulted in a net loss of $23.7 million and $5.3 million for the year ended December 31, 2025 and the six months ended June 30, 2026, respectively.
About Theriva™ Biologics, Inc.
Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company’s subsidiary Theriva Biologics, S.L., has been developing a new oncolytic adenovirus platform designed for intravenous
(IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead clinical-stage candidate is VCN-01 (zabilugene almadenorepvec), an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment.
An exploratory clinical trial remains open with SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients. Enrollment is paused and completion of this trial is pending receipt of grant funding or funding through a partnership or other collaboration. For more information, please visit Theriva™ Biologics’ website at www.therivabio.com.
Forward-Looking Statement
Financial statements
Income Statement
For the three months ended June 30, — (Unaudited) (in thousands)
| For the three months ended June 30, – 2026 | For the three months ended June 30, – 2025 | For the six months ended June 30, – 2026 | For the six months ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| License Revenue | $— | $— | 300 | $— | |
| Operating Costs and Expenses: | General and administrative | 2,027 | 11,179 | 4,099 | 12,628 |
| Operating Costs and Expenses: | Research and development | 1,268 | 1,953 | 1,623 | 4,921 |
| Operating Costs and Expenses: | Total Operating Costs and Expenses | 3,295 | 13,132 | 5,722 | 17,549 |
| Operating Costs and Expenses: | Loss from Operations | -3,295 | -13,132 | -5,422 | -17,549 |
| Other Income/Expense: | Foreign currency exchange (loss) gain | -1 | 20 | 17 | |
| Other Income/Expense: | Interest income | 79 | 54 | 161 | 150 |
| Other Income/Expense: | Total Other Income | 78 | 74 | 161 | 167 |
| Other Income/Expense: | Net Loss before income taxes | -3,217 | -13,058 | -5,261 | -17,382 |
| Other Income/Expense: | Net Loss Attributable to Common Stockholders | -3,217 | -13,058 | -5,261 | -17,382 |
| Other Income/Expense: | Net Loss Per Share - Basic and Dilutive | -0.07 | -1.93 | -0.12 | -3.64 |
| Other Income/Expense: | Weighted average number of shares outstanding during the period - Basic and Dilutive | 45,892,668 | 6,752,953 | 43,496,012 | 4,778,669 |
| Other Income/Expense: | Net Loss | -3,217 | -13,058 | -5,261 | -17,382 |
| Other Income/Expense: | (Loss) gain on foreign currency translation | -130 | 1,317 | -508 | 1,971 |
| Other Income/Expense: | Total comprehensive loss | -3,347 | -11,741 | -5,769 | -15,411 |
Balance Sheet
June 30, 2026 — (In thousands except share and par value amounts)
| June 30, 2026 – (unaudited) | December 31, 2025 | ||
|---|---|---|---|
| Current Assets | Cash and cash equivalents | 11,337 | 13,056 |
| Current Assets | Tax credit receivable | 1,681 | 3,351 |
| Current Assets | Prepaid expenses and other current assets | 653 | 1,060 |
| Current Assets | Total Current Assets | 13,671 | 17,467 |
| Non-Current Assets | Property and equipment, net | 173 | 222 |
| Non-Current Assets | Restricted cash | 44 | 46 |
| Non-Current Assets | Right of use asset | 1,825 | 803 |
| Non-Current Assets | In-process research and development | 19,064 | 19,619 |
| Non-Current Assets | Deposits and other assets | 80 | 82 |
| Non-Current Assets | Total Assets | 34,857 | 38,239 |
| Current Liabilities: | Accounts payable | 984 | 1,014 |
| Current Liabilities: | Accrued expenses | 6,418 | 6,276 |
| Current Liabilities: | Contingent consideration, current portion | 2,650 | |
| Current Liabilities: | Accrued employee benefits | 290 | 443 |
| Current Liabilities: | Deferred research and development tax credit-current portion | 1,210 | 1,675 |
| Current Liabilities: | Loans payable-current | 34 | 57 |
| Current Liabilities: | Operating lease liability-current portion | 525 | 549 |
| Current Liabilities: | Total Current Liabilities | 12,111 | 10,014 |
| Non-current Liabilities | Non-current contingent consideration | 7,169 | 10,004 |
| Non-current Liabilities | Loan Payable - non-current | 1,620 | 1,671 |
| Non-current Liabilities | Non-current deferred research and development tax credit | 396 | 815 |
| Non-current Liabilities | Non-current operating lease liability | 1,374 | 352 |
| Non-current Liabilities | Total Liabilities | 22,670 | 22,856 |
| Stockholders’ Equity: | Common stock, $0.001 par value; 350,000,000 shares authorized, 45,921,478 issued and 45,892,668 outstanding at June 30, 2026, and 35,717,159 issued and 35,688,350 outstanding at December 31, 2025 | 45 | 34 |
| Stockholders’ Equity: | Additional paid-in capital | 376,154 | 373,592 |
| Stockholders’ Equity: | Treasury stock at cost, 28,810 shares at June 30, 2026 and at December 31, 2025 | -288 | -288 |
| Stockholders’ Equity: | Accumulated other comprehensive loss | 247 | 755 |
| Stockholders’ Equity: | Accumulated deficit | -363,971 | -358,710 |
| Stockholders’ Equity: | Total Stockholders’ Equity | 12,187 | 15,383 |
| Stockholders’ Equity: | Total Liabilities and Stockholders’ Equity | 34,857 | 38,239 |
Full release
This release contains forward-looking statements... (truncated)of 1995. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,”
“anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, and include statements regarding the results from the VIRAGE2 trial informing the VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 clinical trial in first-line metastatic PDAC patients when coadministered with chemotherapy; a repeated VCN-01 dosing regimen improving outcomes when combined with other cancer interventions, including immuno-oncology products, RAS inhibitors, and other emerging classes of cancer treatments; more frequent repeated administration of VCN-01 further derisking future Phase 3 clinical trials; more frequent repeated dosing of VCN-01 providing additional clinical benefit; completing enrollment into the VIRAGE2 trial in
H2 2026 with initial pharmacodynamic and safety/tolerability data anticipated by Q3 2027; administering at least 3 doses of VCN-01 in the VIRAGE2 trial given approximately 2 months apart in combination with standard-of-care chemotherapy; the trial enrolling 6 patients; discussing the proposed clinical trial protocol with the FDA in Q3 2026; the findings in the Phase 1 clinical trial of VCN-01 in HNSCC supporting further clinical development of VCN-01 with immune checkpoint inhibitors or other immune modulating anticancer therapies in
HNSCC.. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to finalize protocols for future clinical trials evaluating VCN-01; results of future trials supporting further clinical development of VCN-01 and supporting the benefits of more frequent repeated dosing of VCN-01; the Company’s ability to obtain development funding and/or partnerships; the Company’s commencement of planned clinical trials, which remains subject to sufficient financing; the Company’s ability to raise capital and/or enter into one or more strategic alternatives, that may include a business combination, merger or reverse merger; the Company’s ability to reach clinical milestones when anticipated, including the ability to continue to enroll patients as planned; generating clinical data that establishes VCN-01 may improve patient outcomes in cancer patients; the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements, including approval of VCN-01 to treat cancer patients; regulatory limitations relating to the Company’s ability to promote or commercialize its product candidates for the specific indications; acceptance of the Company’s product candidates in the marketplace; the successful development, marketing or sale of the Company’s products; developments by competitors that render such products obsolete or non-competitive; the Company’s ability to maintain license agreements; the continued maintenance and growth of the Company’s patent estate; the ability to continue to remain well financed; and other factors described in the Company’s Annual Report on Form 10-K for the year ended December 31,
2025 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and current reports on Form 8-K. The information in this release is provided only as of the date of this release, and Theriva Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
For further information, please contact:
Investor Relations
Kevin Gardner
LifeSci Advisors, LLC kgardner@lifesciadvisors.com
Theriva Biologics, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(In thousands except share and par value amounts)
Theriva Biologics, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
(Unaudited)